NCBiotech News

We work hard to bring you news about North Carolina’s wide-ranging life sciences community. Please feel free to share it with others. And let us know if you have something we should know about.

Global pharmaceutical giant Eli Lilly is investing another $450 million and adding at least 100 jobs in an expansion of its nearly completed $474 million Research Triangle Park pharmaceutical manufacturing campus.
Durham pharmaceutical company Eppin Pharma has secured an investment of up to $800,000 from the Male Contraceptive Initiative, a national nonprofit also based in Durham, to help initiate clinical trials for its male birth-control pill.
Oerth Bio, an agricultural biotechnology company in downtown Durham, and Bayer, a global enterprise focused on health care and nutrition, announce a new collaboration and celebrate Oerth’s facilities expansion.
Imagine receiving a COVID-19 vaccine not from the jab of a needle and syringe but by slipping a thin, clear film smaller than a postage stamp inside your cheek or under your tongue and letting it dissolve.
RTP-based Pathalys Pharma has secured $150 million in new financing to support Phase 3 clinical trials for its leading drug candidate to treat end-stage kidney disease.
RTP-based Innatrix is seeking more funding to help it develop its environmentally friendly technology using peptides as a targeted way of controlling agricultural diseases and pests that can devastate crops.
Paris-based Cellectis has successfully dosed its first U.S. patient with its UCART22 allogeneic CAR T-cell therapy product candidate that it made in its new Raleigh facility.
Boone-based MOLTOX gets International Organization for Standardization ISO 9001:2015 certification.
There'll be job info galore at the free public Biomanufacturing and Process Development BioGrow Training and Education Symposium on Thursday, Feb. 9, from 12:30 to 5 p.m. at NCBiotech.
Target RWE, a Durham-based clinical analytics company, has launched 35 new observational disease-state registries to support decision-making in health care.
Chaseman Global, an international life sciences executive recruitment company, opened a regional office today at the North Carolina Biotechnology Center’s Landing Pad rental office site.
RTP-based AskBio has signed a multi-year research collaboration and option agreement with Bay-area firm ReCode Therapeutics to develop gene-editing technology for driving new precision therapies.
Datar Cancer Genetics, a global company developing blood-based diagnostics for cancer, with a U.S. base in Morrisville, has received the FDA’s breakthrough devices designation for its non-invasive test to help diagnose brain tumors.
Life sciences and related companies from around the world announced new or expanded facilities in 2022 that will bring more than $2.1 billion in investment and over 2,700 new jobs to North Carolina.
scroll back to top of page